A Phase 3 interventional study of eltrombopag and placebo in Hepatitis C, Chronic, sponsored by GlaxoSmithKline. Completed at 227 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-05.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hepatitis C, Chronic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · GlaxoSmithKline.
Among the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline, this one is the 3rd largest by enrollment, is one of 3 that started in 2007, is one of 4 in phase 3, and was the 8th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline is open now. The open studies under Hepatitis C, Chronic, anywhere →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 759 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 62 across the 14 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female subjects, >18 years Evidence of chronic virus (HCV) infection Subjects who are appropriate candidates for peginterferon (pegIFN) and ribavirin antiviral therapy A count of \<75,000/mcL >11.0g/dL for men or >10.0g/dL for women (ANC) >750/mm3 and no history of infections associated with neutropenia >50mL/minute All fertile males and females must use two forms of effective between them during treatment and during the 24 weeks after treatment end Subject is able to understand, consent and comply with protocol requirements and instructions and is likely to complete the study as planned
Exclusion criteria:
Non-responders to previous treatment with pegIFN and ribavirin who failed to achieve a sustained virologic response (SVR) for reasons other than thrombocytopenia, despite an optimal course (dose and duration) of combination therapy with pegIFN and ribavirin Decompensated liver disease, e.g. score >6 or history of ascites or hepatic encephalopathy or current evidence of ascites Known , intolerance or allergy to interferon (IFN), ribavirin, eltrombopag or any of their ingredients Serious cardiac, cerebrovascular, or pulmonary disease that would preclude treatment with pegIFN and ribavirin
Subjects with a history of any one of the following:
Suicide attempt or hospitalisation for depression in the past 5 years Any current severe or poorly controlled psychiatric disorder
The following subjects are eligible for study participation, but must be assessed and followed (if recommended) by a mental health professional:
Subjects who have had a diagnosed and/or treated within the past 5 years, except for subjects with localised basal or squamous cell carcinoma treated by local excision or subjects with malignancies who have been adequately treated and, in the opinion of the oncologist, have an excellent chance of cancer-free survival Pregnant or nursing women Males with a female partner who is pregnant History of alcohol/drug abuse or dependence within 6 months of the study start (unless participating in a controlled rehabilitation programme) Treatment with an drug or IFN within 30 days or 5 half-lives (whichever is longer) of the screening visit History of clumping that prevents reliable measurement of platelet counts History of major organ transplantation with an existing functional graft Thyroid dysfunction not adequately controlled Subjects planning to have cataract surgery Evidence of portal vein thrombosis on abdominal imaging within 3 months of the baseline visit
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
active treatment arm
Drug: eltrombopag
placebo control arm
Drug: placebo
double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
double-blind matched placebo control daily oral administration
Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase
Participants with SVR are defined as those with non-detectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) at the end of treatment and all subsequent planned visits up to 24 weeks post-completion of the treatment period of the DB Phase.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase
Participants were assessed for a shift from a baseline platelet count of \<75 Gi/L to a count \>=100 Gi/L during the OL Phase (up to 9 weeks). Local laboratories were used for platelet function tests. Platelet counts were measured by blood draw.
Time frame: From Baseline up to Week 9 in the OL Phase
Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase
In the OL Phase, participants initially received the lowest dose of eltrombopag (25 mg QD) for 2 weeks. If after this time the platelet count was \<100 Gi/L, participants underwent sequential dose escalation to the next highest dose (50 mg QD for up to 2 weeks), with further dose escalations to 75 mg QD (up to 2 weeks) and 100 mg QD (up to a maximum of 3 weeks) if platelet counts remained \<100 Gi/L. Participants who achieved platelet counts \>=100 Gi/L when receiving any of the eltrombopag doses in the OL Phase initiated antiviral therapy in the DB Phase.
Time frame: From Baseline up to Week 9 in the OL Phase
Median Platelet Count at the Indicated Time Points During the OL Phase
Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.
Time frame: OL Phase: Baseline; Day 1; Weeks 1, 2, 3, 4, 5, 6, 7, 8, and 9; Antiviral Baseline (up to Week 10); End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 62); 12-week FU (up to Week 70); and 24-week FU (up to Week 82)
Median Platelet Count at the Indicated Time Points During the DB Phase
Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.
Time frame: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy
The minimum platelet count with antiviral therapy was categorized as follows: \<25 Gi/L; \>=25 to \<50 Gi/L; \>=50 to \<90 Gi/L; \>=90 to \<150 Gi/L; \>=150 Gi/L to \<200 Gi/L; \>=200 Gi/L to \<400 Gi/L; and \>=400 Gi/L.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase
RVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment. eRVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment that persisted through Week 12.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase
EVR is defined as a clinically significant reduction from Baseline in HCV RNA (\>=2 log10 drop or undetectable) after 12 weeks of antiviral treatment. cEVR is defined as undetectable HCV RNA after 12 weeks of antiviral treatment.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase
ETR is defined as the absence of detectable HCV RNA at the end of antiviral treatment. SVR12 is defined as the absence of detectable HCV RNA at the end of antiviral treatment and the 12-week follow-up assessment.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase
Participants were assigned a score equal to the number of times their dose of antiviral therapy (peginterferon or ribavirin) was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). When possible, every effort was made to maintain the recommended dose of antiviral therapy for the treatment duration in the DB Phase. However, when dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of peginterferon and ribavirin.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase
Time to first dose reduction was calculated as the time period from the first dose to the first dose reduction.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase
The assigned dose in the DB Phase of peginterferon alfa-2a was 180 micrograms (µg). For peginterferon dose modification, downward adjustments in one-level increments were considered. The lowest dose of peginterferon alfa-2a that was allowed to be administered was 45 µg. When dose adjustment was required for moderate to severe adverse reactions (clinical and/or laboratory), an initial dose reduction to 135 µg was generally adequate. In some cases, a dose reduction to 90 µg or 45 µg was necessary. Dose increases toward the original dose were considered when the adverse reaction was resolved.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase
The following participants were considered to have discontinued antiviral therapy: participants who were lost to follow-up; participants who withdrew for any reason; participants who died; participants who otherwise did not complete their planned course of antiviral therapy for any reason. The planned duration of antiviral therapy was 48 weeks for participants with Non-Genotype 2/3 and 24 or 48 weeks for participants with Genotype 2/3.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3)
There are two genetic variants (rs12979860 and rs8099917) mapping near IL28B associated with both interferon-induced SVR and spontaneous HCV clearance. IL28B genotype distribution by response to antiviral therapy (SVR/RVR responders: those who achieved SVR/RVR; SVR/RVR non-responders: those who did not achieve SVR/RVR) was assessed. The effect of genotype was tested by comparing participants that carried 2 copies of the IL28B favorable response allele versus the others (recessive model). Genotypes at rs12979860 were coded as: CC=1, CT or TT=0; rs8099917 was coded as TT=1, GT or GG=0.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS)
Blood samples for the assessment of clinical chemistry parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of calcium (low=hypocalcemia; high=hypercalcemia), glu. (low=hypoglycemia; high=hyperglycemia), pot. (low=hypokalemia; high=hyperkalemia), and sod. (low=hyponatremia; high=hypernatremia). Per the DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS
Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication
Ophthalmic (pertaining to eye) assessments were performed during the study. A cataract event is defined as an event ascertained to be a cataract (opacity or cloudiness of the lens of the eye, causing impairment of vision) by at least one of the CEC members (comprised of expert ophthalmologists who provided objective medical review of the blinded ophthalmic data). Per the CEC, cataract events were categorized as: (1) Cataract Progression (CP; progression of cataracts present at BL); and (2) Incident Cataract (IC; development of new cataracts). One eye=unilateral; both eyes=bilateral.
Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase
Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal, all ECG parameters within accepted normal ranges. Abnormal, ECG finding(s) outside of normal ranges. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.
Time frame: DB Phase: Antiviral BL (up to Week 10); End of Treatment (up to Week 52); and 24-week FU (up to Week 72)
Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase
Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with a CS and a NCS change from baseline in ECG status, as determined by the Investigator, was reported. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment. "Not applicable" indicates that information was not provided by the investigator on whether the change from baseline ECG was CS or NCS.
Time frame: End of Treatment (up to Week 52); and 24-week FU (up to Week 72)
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase
Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase
Heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase
The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
| Milestone | Eltrombopag: Open-label Phase | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|---|
| Started | 805 | 0 | 0 |
| Completed | 759 | 0 | 0 |
| Not completed | 46 | 0 | 0 |
| Withdrew: Adverse event | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 12 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 0 | 0 |
| Withdrew: Physician decision | 8 | 0 | 0 |
| Withdrew: Insufficient platelet response | 13 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 |
| Milestone | Eltrombopag: Open-label Phase | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|---|
| Started | 0 | 253 | 506 |
| Completed | 0 | 205 | 404 |
| Not completed | 0 | 48 | 102 |
| Withdrew: Adverse event | 0 | 10 | 27 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 15 | 48 |
| Withdrew: Physician decision | 0 | 5 | 8 |
| Withdrew: Withdrawal by subject | 0 | 17 | 19 |
Participants with SVR are defined as those with non-detectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) at the end of treatment and all subsequent planned visits up to 24 weeks post-completion of the treatment period of the DB Phase.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase | 32 | 97 |
Participants were assessed for a shift from a baseline platelet count of \<75 Gi/L to a count \>=100 Gi/L during the OL Phase (up to 9 weeks). Local laboratories were used for platelet function tests. Platelet counts were measured by blood draw.
| participants | Eltrombopag: OL Phase |
|---|---|
| Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase | 773 |
In the OL Phase, participants initially received the lowest dose of eltrombopag (25 mg QD) for 2 weeks. If after this time the platelet count was \<100 Gi/L, participants underwent sequential dose escalation to the next highest dose (50 mg QD for up to 2 weeks), with further dose escalations to 75 mg QD (up to 2 weeks) and 100 mg QD (up to a maximum of 3 weeks) if platelet counts remained \<100 Gi/L. Participants who achieved platelet counts \>=100 Gi/L when receiving any of the eltrombopag doses in the OL Phase initiated antiviral therapy in the DB Phase.
| participants | Eltrombopag: OL Phase |
|---|---|
| 25 mg | 443 |
| 50 mg | 208 |
| 75 mg | 77 |
| 100 mg | 31 |
Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.
| Gi/L | Eltrombopag: OL Phase |
|---|---|
| Baseline, n=797 | 59.0 (12 to 95) |
| Day 1, n=714 | 58.0 (5 to 117) |
| Week 1, n=791 | 77.0 (5 to 223) |
| Week 2, n=530 | 93.0 (9 to 489) |
| Week 3, n=288 | 89.0 (10 to 504) |
| Week 4, n=161 | 90.0 (10 to 280) |
| Week 5, n=98 | 92.0 (9 to 252) |
| Week 6, n=55 | 86.0 (14 to 138) |
| Week 7, n=35 | 78.0 (11 to 136) |
| Week 8, n=24 | 87.5 (15 to 146) |
| Week 9, n=4 | 85.5 (66 to 107) |
| Antiviral Baseline, n=48 | 131.5 (76 to 274) |
| End of Treatment/Withdrawal, n=22 | 76.5 (13 to 257) |
| Last on Treatment, n=39 | 87.0 (13 to 267) |
| Week 4 Follow-Up, n=20 | 42.0 (11 to 156) |
| Week 12 Follow-Up, n=15 | 43.0 (8 to 91) |
| Week 24 Follow-Up, n=14 | 41.0 (13 to 87) |
Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.
| Gi/L | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Baseline, n=238, 460 | 140.0 (63 to 365) | 136.0 (43 to 400) |
| Week 1, n=247, 494 | 120.0 (42 to 366) | 116.0 (46 to 466) |
| Week 2, n=244, 492 | 89.5 (27 to 318) | 124.0 (38 to 553) |
| Week 4, n=228, 487 | 51.0 (20 to 180) | 105 (19 to 389) |
| Week 6, n=206, 473 | 49.5 (20 to 200) | 100.0 (22 to 417) |
| Week 8, n=192, 473 | 50.0 (10 to 191) | 100.0 (19 to 486) |
| Week 12, n=176, 451 | 49.7 (21 to 264) | 104.0 (10 to 444) |
| Week 16, n=145, 405 | 48.0 (20 to 262) | 102.0 (13 to 365) |
| Week 20, n=134, 378 | 50.0 (23 to 257) | 103.0 (21 to 373) |
| Week 24, n=99, 263 | 49.0 (19 to 200) | 102.0 (18 to 448) |
| Week 28, n=74, 212 | 52.5 (22 to 193) | 102.0 (20 to 355) |
| Week 32, n=67, 199 | 49.0 (22 to 195) | 107.0 (14 to 295) |
| Week 36, n=63, 185 | 50.0 (16 to 198) | 106.0 (29 to 268) |
| Week 40, n=58, 174 | 53.7 (19 to 195) | 106.5 (10 to 351) |
| Week 44, n=59, 168 | 53.0 (26 to 197) | 108.7 (26 to 330) |
| End of Treatment/Withdrawal, n=240, 468 | 51.0 (10 to 275) | 106.5 (10 to 445) |
| Last on Treatment, n=253, 505 | 50.0 (17 to 300) | 105.0 (10 to 330) |
| 4 week follow up, n=221, 424 | 63.0 (4 to 225) | 89.0 (12 to 333) |
| 12 week follow up, n=209, 430 | 57.0 (15 to 285) | 62.0 (8 to 280) |
| 24 week follow up, n=201, 395 | 57.0 (8 to 231) | 59.0 (4 to 297) |
The minimum platelet count with antiviral therapy was categorized as follows: \<25 Gi/L; \>=25 to \<50 Gi/L; \>=50 to \<90 Gi/L; \>=90 to \<150 Gi/L; \>=150 Gi/L to \<200 Gi/L; \>=200 Gi/L to \<400 Gi/L; and \>=400 Gi/L.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| <25 Gi/L | 34 | 20 |
| >=25 to <50 Gi/L | 159 | 76 |
| >=50 to <90 Gi/L | 49 | 263 |
| >=90 to <150 Gi/L | 10 | 135 |
| >=150 to <200 Gi/L | 0 | 8 |
| >=200 to <400 Gi/L | 0 | 4 |
| >=400 Gi/L | 0 | 0 |
| Missing | 1 | 0 |
RVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment. eRVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment that persisted through Week 12.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| RVR | 34 | 78 |
| eRVR | 27 | 69 |
EVR is defined as a clinically significant reduction from Baseline in HCV RNA (\>=2 log10 drop or undetectable) after 12 weeks of antiviral treatment. cEVR is defined as undetectable HCV RNA after 12 weeks of antiviral treatment.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| EVR | 103 | 313 |
| cEVR | 57 | 174 |
ETR is defined as the absence of detectable HCV RNA at the end of antiviral treatment. SVR12 is defined as the absence of detectable HCV RNA at the end of antiviral treatment and the 12-week follow-up assessment.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| ETR | 59 | 190 |
| SVR12 | 29 | 106 |
Participants were assigned a score equal to the number of times their dose of antiviral therapy (peginterferon or ribavirin) was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). When possible, every effort was made to maintain the recommended dose of antiviral therapy for the treatment duration in the DB Phase. However, when dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of peginterferon and ribavirin.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| 0 | 68 | 231 |
| 1 | 76 | 101 |
| 2 | 40 | 75 |
| 3 | 34 | 47 |
| >3 | 35 | 52 |
Time to first dose reduction was calculated as the time period from the first dose to the first dose reduction.
| weeks | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Peginterferon alfa-2a dose reduction, n=171, 208 | 6.58 ± 7.336 | 10.64 ± 9.305 |
| Ribavirin dose reduction, n=79, 189 | 12.43 ± 9.681 | 10.99 ± 8.984 |
The assigned dose in the DB Phase of peginterferon alfa-2a was 180 micrograms (µg). For peginterferon dose modification, downward adjustments in one-level increments were considered. The lowest dose of peginterferon alfa-2a that was allowed to be administered was 45 µg. When dose adjustment was required for moderate to severe adverse reactions (clinical and/or laboratory), an initial dose reduction to 135 µg was generally adequate. In some cases, a dose reduction to 90 µg or 45 µg was necessary. Dose increases toward the original dose were considered when the adverse reaction was resolved.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| <=25% | 44 | 89 |
| >25% to <=34% | 33 | 35 |
| >34% to <=50% | 115 | 112 |
| >50% | 33 | 30 |
The following participants were considered to have discontinued antiviral therapy: participants who were lost to follow-up; participants who withdrew for any reason; participants who died; participants who otherwise did not complete their planned course of antiviral therapy for any reason. The planned duration of antiviral therapy was 48 weeks for participants with Non-Genotype 2/3 and 24 or 48 weeks for participants with Genotype 2/3.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase | 164 | 242 |
There are two genetic variants (rs12979860 and rs8099917) mapping near IL28B associated with both interferon-induced SVR and spontaneous HCV clearance. IL28B genotype distribution by response to antiviral therapy (SVR/RVR responders: those who achieved SVR/RVR; SVR/RVR non-responders: those who did not achieve SVR/RVR) was assessed. The effect of genotype was tested by comparing participants that carried 2 copies of the IL28B favorable response allele versus the others (recessive model). Genotypes at rs12979860 were coded as: CC=1, CT or TT=0; rs8099917 was coded as TT=1, GT or GG=0.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| SVR, rs12979860 (CC), R; n=12, 50 | 10 | 28 |
| SVR, rs12979860 (CC), NR; n=105, 205 | 24 | 58 |
| SVR, rs12979860 (CT), R; n=12, 50 | 2 | 18 |
| SVR, rs12979860 (CT), NR; n=105, 205 | 60 | 111 |
| SVR, rs12979860 (TT), R; n=12, 50 | 0 | 4 |
| SVR, rs12979860 (TT), NR; n=105, 205 | 21 | 36 |
| SVR, rs8099917 (TT), R; n=12, 50 | 11 | 36 |
| SVR, rs8099917 (TT), NR; n=105, 205 | 48 | 89 |
| SVR, rs8099917 (GT), R; n=12, 50 | 1 | 13 |
| SVR, rs8099917 (GT), NR; n=105, 205 | 51 | 99 |
| SVR, rs8099917 (GG), R; n=12, 50 | 0 | 1 |
| SVR, rs8099917 (GG), NR; n=105, 205 | 6 | 17 |
| RVR, rs12979860 (CC), R; n=11, 33 | 6 | 21 |
| RVR, rs12979860 (CC), NR; n=106, 222 | 28 | 65 |
| RVR, rs12979860 (CT), R; n=11, 33 | 5 | 11 |
| RVR, rs12979860 (CT), NR; n=106, 222 | 57 | 118 |
| RVR, rs12979860 (TT), R; n=11, 33 | 0 | 1 |
| RVR, rs12979860 (TT), NR; n=106, 222 | 21 | 39 |
| RVR, rs8099917 (TT), R, n=11, 33 | 9 | 28 |
| RVR, rs8099917 (TT), NR; n=106, 222 | 50 | 97 |
| RVR, rs8099917 (GT), R; n=11, 33 | 2 | 5 |
| RVR, rs8099917 (GT), NR; n=106, 222 | 50 | 107 |
| RVR, rs8099917 (GG), R; n=11, 33 | 0 | 0 |
| RVR, rs8099917 (GG), R; n=106, 222 | 6 | 18 |
Blood samples for the assessment of clinical chemistry parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of calcium (low=hypocalcemia; high=hypercalcemia), glu. (low=hypoglycemia; high=hyperglycemia), pot. (low=hypokalemia; high=hyperkalemia), and sod. (low=hyponatremia; high=hypernatremia). Per the DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Calcium (hypocalcemia), Any Grade Increase | 184 | 374 |
| Calcium (hypocalcemia), Increase to G1 | 140 | 246 |
| Calcium (hypocalcemia), Increase to G2 | 42 | 122 |
| Calcium (hypocalcemia), Increase to G3 | 2 | 4 |
| Calcium (hypocalcemia), Increase to G4 | 0 | 2 |
| Calcium (hypercalcemia), Any Grade Increase | 2 | 1 |
| Calcium (hypercalcemia), Increase to G1 | 1 | 1 |
| Calcium (hypercalcemia), Increase to G2 | 1 | 0 |
| Calcium (hypercalcemia), Increase to G3 | 0 | 0 |
| Calcium (hypercalcemia), Increase to G4 | 0 | 0 |
| Glu. (hypoglycemia), Any Grade Increase | 31 | 90 |
| Glu. (hypoglycemia), Increase to G1 | 17 | 45 |
| Glu. (hypoglycemia), Increase to G2 | 10 | 31 |
| Glu. (hypoglycemia), Increase to G3 | 4 | 9 |
| Glu. (hypoglycemia), Increase to G4 | 0 | 5 |
| Glu. (hyperglycemia), Any Grade Increase | 128 | 277 |
| Glu. (hyperglycemia), Increase to G1 | 31 | 68 |
| Glu. (hyperglycemia), Increase to G2 | 77 | 161 |
| Glu. (hyperglycemia), Increase to G3 | 19 | 44 |
| Glu. (hyperglycemia), Increase to G4 | 1 | 4 |
| Pot. (hyperkalemia), Any Grade Increase | 3 | 15 |
| Pot. (hyperkalemia), Increase to G1 | 2 | 7 |
| Pot. (hyperkalemia), Increase to G2 | 1 | 3 |
| Pot. (hyperkalemia), Increase to G3 | 0 | 2 |
| Pot. (hyperkalemia), Increase to G4 | 0 | 3 |
| Pot. (hypokalemia), Any Grade Increase | 53 | 74 |
| Pot. (hypokalemia), Increase to G1 | 48 | 66 |
| Pot. (hypokalemia), Increase to G2 | 5 | 6 |
| Pot. (hypokalemia), Increase to G3 | 0 | 2 |
| Pot. (hypokalemia), Increase to G4 | 0 | 0 |
| Sod. (hypernatremia), Any Grade Increase | 14 | 21 |
| Sod. (hypernatremia), Increase to G1 | 14 | 20 |
| Sod. (hypernatremia), Increase to G2 | 0 | 1 |
| Sod. (hypernatremia), Increase to G3 | 0 | 0 |
| Sod. (hypernatremia), Increase to G4 | 0 | 0 |
| Sod. (hyponatremia), Any Grade Increase | 72 | 128 |
| Sod. (hyponatremia), Increase to G1 | 69 | 118 |
| Sod. (hyponatremia), Increase to G2 | 3 | 8 |
| Sod. (hyponatremia), Increase to G3 | 0 | 1 |
| Sod. (hyponatremia), Increase to G4 | 0 | 1 |
Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Hemoglobin (anemia), Any Grade Increase | 161 | 361 |
| Hemoglobin (anemia), Increase to G1 | 46 | 112 |
| Hemoglobin (anemia), Increase to G2 | 64 | 129 |
| Hemoglobin (anemia), Increase to G3 | 48 | 114 |
| Hemoglobin (anemia), Increase to G4 | 3 | 6 |
| Lym. (lymphocytopenia), Any Grade Increase | 136 | 346 |
| Lym. (lymphocytopenia), Increase to G1 | 16 | 43 |
| Lym. (lymphocytopenia), Increase to G2 | 38 | 80 |
| Lym. (lymphocytopenia), Increase to G3 | 48 | 109 |
| Lym. (lymphocytopenia), Increase to G4 | 34 | 114 |
| Tot Neu. (neutropenia), Any Grade Increase | 208 | 394 |
| Tot Neu. (neutropenia), Increase to G1 | 50 | 106 |
| Tot Neu. (neutropenia), Increase to G2 | 53 | 113 |
| Tot Neu. (neutropenia), Increase to G3 | 73 | 128 |
| Tot Neu. (neutropenia), Increase to G4 | 32 | 47 |
| WBC (leukocytopenia), Any Grade Increase | 191 | 391 |
| WBC (leukocytopenia), Increase to G1 | 56 | 113 |
| WBC (leukocytopenia), Increase to G2 | 69 | 145 |
| WBC (leukocytopenia), Increase to G3 | 58 | 110 |
| WBC (leukocytopenia), Increase to G4 | 8 | 23 |
Ophthalmic (pertaining to eye) assessments were performed during the study. A cataract event is defined as an event ascertained to be a cataract (opacity or cloudiness of the lens of the eye, causing impairment of vision) by at least one of the CEC members (comprised of expert ophthalmologists who provided objective medical review of the blinded ophthalmic data). Per the CEC, cataract events were categorized as: (1) Cataract Progression (CP; progression of cataracts present at BL); and (2) Incident Cataract (IC; development of new cataracts). One eye=unilateral; both eyes=bilateral.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Unilateral CP, Genotype 2/3 | 0 | 1 |
| Unilateral CP, Non-genotype 2/3 | 4 | 6 |
| Bilateral CP, Genotype 2/3 | 3 | 1 |
| Bilateral CP, Non-genotype 2/3 | 1 | 7 |
| Unilateral IP, Genotype 2/3 | 1 | 4 |
| Unilateral IP, Non-genotype 2/3 | 1 | 6 |
| Bilateral IP, Genotype 2/3 | 3 | 1 |
| Bilateral IP, Non-genotype 2/3 | 3 | 10 |
Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal, all ECG parameters within accepted normal ranges. Abnormal, ECG finding(s) outside of normal ranges. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Antiviral BL, Normal, n=232, 478 | 147 | 332 |
| Antiviral BL, Abnormal - NCS, n=232, 478 | 63 | 103 |
| Antiviral BL, Abnormal - CS, n=232, 478 | 22 | 43 |
| End of Treatment, Normal, n=218, 428 | 134 | 291 |
| End of Treatment, Abnormal - NCS, n=218, 428 | 62 | 103 |
| End of Treatment, Abnormal - CS, n=218, 428 | 22 | 34 |
| 24-week FU, Normal, n=194, 383 | 123 | 238 |
| 24-week FU, Abnormal - NCS, n=194, 383 | 49 | 107 |
| 24-week FU, Abnormal - CS, n=194, 383 | 22 | 38 |
| Worst ECG post-BL, Normal, n=252, 505 | 113 | 233 |
| Worst ECG post-BL, Abnormal - NCS, n=252, 505 | 91 | 171 |
| Worst ECG post-BL, Abnormal - CS, n=252, 505 | 48 | 101 |
Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with a CS and a NCS change from baseline in ECG status, as determined by the Investigator, was reported. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment. "Not applicable" indicates that information was not provided by the investigator on whether the change from baseline ECG was CS or NCS.
| participants | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| End of Treatment, CS change from BL, n=218, 428 | 0 | 7 |
| End of Treatment, NCS change from BL, n=218, 428 | 218 | 420 |
| End of Treatment, Not applicable, n=218, 428 | 0 | 1 |
| 24-week FU, CS change from BL, n=194, 383 | 1 | 4 |
| 24-week FU, NCS change from BL, n=194, 383 | 193 | 379 |
Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
| Millimeters of mercury (mmHg) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| SBP, Week 1, n=246, 491 | -3.00 ± 13.541 | -2.36 ± 12.296 |
| SBP, Week 2, n=242, 494 | -3.25 ± 13.800 | -3.74 ± 13.122 |
| SBP, Week 4, n=228, 485 | -3.75 ± 13.781 | -3.91 ± 13.780 |
| SBP, Week 6, n=206, 471 | -3.36 ± 14.405 | -3.85 ± 14.624 |
| SBP, Week 8, n=190, 472 | -2.72 ± 14.073 | -4.33 ± 14.401 |
| SBP, Week 12, n=175, 452 | -2.16 ± 15.297 | -4.30 ± 14.377 |
| SBP, Week 16, n=143, 403 | -3.16 ± 15.426 | -4.59 ± 13.579 |
| SBP, Week 20, n=133, 374 | -2.50 ± 14.387 | -4.12 ± 14.908 |
| SBP, Week 24, n=99, 263 | -1.97 ± 14.820 | -3.94 ± 14.917 |
| SBP, Week 28, n=74, 211 | -0.69 ± 14.663 | -4.99 ± 14.557 |
| SBP, Week 32, n=67, 197 | -1.46 ± 13.904 | -5.61 ± 13.523 |
| SBP, Week 36, n=62, 186 | -1.31 ± 13.803 | -4.40 ± 14.842 |
| SBP, Week 40, n=59, 173 | 0.10 ± 13.605 | -4.31 ± 13.941 |
| SBP, Week 44, n=59, 167 | 0.56 ± 11.689 | -4.54 ± 13.794 |
| SBP, End of Treatment, n=238, 468 | -2.03 ± 13.259 | -3.98 ± 15.318 |
| SBP, 4-week FU, n=221, 426 | -1.14 ± 14.095 | -1.65 ± 15.122 |
| SBP, 12-week FU, n=207, 432 | -0.11 ± 14.113 | -0.86 ± 14.806 |
| SBP, 24-week FU, n=203, 398 | 1.10 ± 14.545 | 0.25 ± 14.518 |
| DBP, Week 1, n=246, 491 | -1.43 ± 9.235 | -1.37 ± 8.224 |
| DBP, Week 2, n=242, 493 | -1.55 ± 9.217 | -1.86 ± 8.946 |
| DBP, Week 4, n=228, 485 | -1.84 ± 9.726 | -2.72 ± 9.467 |
| DBP, Week 6, n=206, 471 | -2.16 ± 8.939 | -2.95 ± 9.859 |
| DBP, Week 8, n=190, 472 | -1.24 ± 9.517 | -2.68 ± 9.901 |
| DBP, Week 12, n=175, 452 | -1.31 ± 8.781 | -3.23 ± 10.025 |
| DBP, Week 16, n=143, 403 | -1.54 ± 9.684 | -3.31 ± 9.899 |
| DBP, Week 20, n=133, 374 | -0.93 ± 10.582 | -3.08 ± 9.606 |
| DBP, Week 24, n=99, 263 | -1.66 ± 10.207 | -3.54 ± 9.313 |
| DBP, Week 28, n=74, 211 | -1.23 ± 9.538 | -3.42 ± 10.502 |
| DBP, Week 32, n=67, 197 | -0.54 ± 10.445 | -3.76 ± 9.527 |
| DBP, Week 36, n=62, 186 | -0.74 ± 9.559 | -3.59 ± 9.211 |
| DBP, Week 40, n=59, 173 | 0.34 ± 9.343 | -3.32 ± 9.517 |
| DBP, Week 44, n=59, 167 | 0.92 ± 9.033 | -3.77 ± 10.134 |
| DBP, End of Treatment, n=238, 468 | -1.55 ± 9.174 | -3.59 ± 10.254 |
| DBP, 4-week FU, n=221, 426 | -0.83 ± 9.102 | -2.20 ± 9.824 |
| DBP, 12-week FU, n=207, 432 | -0.78 ± 10.253 | -1.76 ± 9.903 |
| DBP, 24-week FU, n=203, 398 | 0.03 ± 9.814 | -1.61 ± 9.339 |
Heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
| beats per minute | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Week 1, n=244, 490 | 1.16 ± 8.358 | -0.43 ± 8.629 |
| Week 2, n=242, 490 | 1.89 ± 8.510 | 0.78 ± 9.644 |
| Week 4, n=227, 483 | 2.47 ± 9.464 | 1.50 ± 9.739 |
| Week 6, n=205, 470 | 3.23 ± 9.158 | 1.19 ± 8.708 |
| Week 8, n=190, 472 | 2.91 ± 9.751 | 1.78 ± 9.227 |
| Week 12, n=174, 450 | 4.28 ± 10.188 | 2.02 ± 9.539 |
| Week 16, n=143, 403 | 5.87 ± 9.975 | 2.38 ± 10.419 |
| Week 20, n=132, 371 | 5.73 ± 9.688 | 2.10 ± 9.530 |
| Week 24, n=99, 262 | 3.77 ± 9.912 | 2.03 ± 9.399 |
| Week 28, n=74, 211 | 2.72 ± 10.038 | 1.64 ± 10.328 |
| Week 32, n=67, 196 | 4.28 ± 8.281 | 1.62 ± 9.676 |
| Week 36, n=62, 186 | 5.42 ± 10.109 | 2.11 ± 10.205 |
| Week 40, n=59, 171 | 4.83 ± 8.919 | 0.78 ± 9.895 |
| Week 44, n=59, 165 | 5.53 ± 11.005 | 1.16 ± 8.846 |
| End of Treatment, n=237, 467 | 4.01 ± 10.606 | 2.89 ± 11.134 |
| 4-week FU, n=220, 422 | 4.27 ± 10.432 | 2.11 ± 10.113 |
| 12-week FU, n=206, 429 | 1.73 ± 9.707 | 0.74 ± 9.955 |
| 24-week FU, n=202, 395 | 0.14 ± 9.803 | -1.90 ± 9.176 |
The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
| Kilograms (kg) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Week 1, n=248, 492 | -0.65 ± 2.201 | -0.68 ± 2.062 |
| Week 2, n=244, 495 | -0.88 ± 1.983 | -1.06 ± 2.809 |
| Week 4, n=229, 488 | -1.30 ± 2.374 | -1.30 ± 2.488 |
| Week 6, n=207, 476 | -1.42 ± 2.464 | -1.68 ± 2.652 |
| Week 8, n=191, 473 | -1.89 ± 2.793 | -2.11 ± 2.810 |
| Week 12, n=175, 453 | -2.18 ± 2.985 | -2.83 ± 3.440 |
| Week 16, n=145, 406 | -2.37 ± 3.247 | -3.32 ± 3.798 |
| Week 20, n=134, 378 | -3.08 ± 3.684 | -3.99 ± 4.040 |
| Week 24, n=99, 265 | -4.04 ± 4.148 | -4.75 ± 4.175 |
| Week 28, n=74, 212 | -4.57 ± 4.749 | -5.09 ± 5.016 |
| Week 32, n=67, 200 | -4.50 ± 4.397 | -5.52 ± 5.369 |
| Week 36, n=63, 188 | -4.54 ± 4.739 | -5.39 ± 7.476 |
| Week 40, n=59, 174 | -4.99 ± 4.612 | -5.87 ± 5.571 |
| Week 44, n=59, 168 | -4.79 ± 5.475 | -5.89 ± 5.661 |
| End of Treatment, n=240, 470 | -3.28 ± 4.361 | -4.69 ± 5.180 |
| 4-week FU, n=223, 425 | -2.78 ± 4.318 | -3.84 ± 6.381 |
| 12-week FU, n=210, 434 | -1.98 ± 4.088 | -2.99 ± 5.999 |
| 24-week FU, n=205, 401 | -1.36 ± 4.568 | -1.51 ± 7.683 |
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
| Kilograms per meters squared (kg/m^2) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|
| Week 1, n=248, 490 | -0.23 ± 0.771 | -0.23 ± 0.713 |
| Week 2, n=244, 493 | -0.31 ± 0.691 | -0.36 ± 0.921 |
| Week 4, n=229, 486 | -0.46 ± 0.823 | -0.45 ± 0.855 |
| Week 6, n=207, 474 | -0.50 ± 0.871 | -0.58 ± 0.893 |
| Week 8, n=191, 471 | -0.66 ± 0.967 | -0.73 ± 0.955 |
| Week 12, n=175, 451 | -0.77 ± 1.055 | -0.97 ± 1.167 |
| Week 16, n=145, 404 | -0.85 ± 1.158 | -1.15 ± 1.285 |
| Week 20, n=134, 376 | -1.11 ± 1.324 | -1.39 ± 1.377 |
| Week 24, n=99, 264 | -1.46 ± 1.509 | -1.66 ± 1.624 |
| Week 28, n=74, 211 | -1.67 ± 1.731 | -1.79 ± 1.733 |
| Week 32, n=67, 199 | -1.64 ± 1.586 | -1.94 ± 1.844 |
| Week 36, n=63, 187 | -1.65 ± 1.703 | -1.89 ± 2.651 |
| Week 40, n=59, 173 | -1.81 ± 1.671 | -2.09 ± 1.953 |
| Week 44, n=59, 167 | -1.73 ± 2.007 | -2.09 ± 1.942 |
| End of Treatment, n=240, 468 | -1.16 ± 1.553 | -1.64 ± 1.783 |
| 4-week FU, n=223, 423 | -0.98 ± 1.519 | -1.35 ± 2.306 |
| 12-week FU, n=210, 432 | -0.70 ± 1.434 | -1.06 ± 2.055 |
| 24-week FU, n=205, 399 | -0.47 ± 1.544 | -0.53 ± 2.736 |
Collected over Adverse events (AEs) are reported for the Double-blind (DB) on-treatment + 30 days period (up to Study Week 52).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag: OL Phase | — | 9/805 (1.1%) | 0/805 (0%) |
| Placebo+Antiviral Therapy: DB Phase | — | 49/252 (19.4%) | 226/252 (89.7%) |
| Eltrombopag+Antiviral Therapy: DB Phase | — | 119/506 (23.5%) | 459/506 (90.7%) |
| Event | Eltrombopag: OL Phase | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|---|
| Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/805 | 7/252 | 22/506 |
| Hepatic encephalopathyNervous system disorders | 0/805 | 1/252 | 9/506 |
| CataractEye disorders | 0/805 | 1/252 | 9/506 |
| PneumoniaInfections and infestations | 1/805 | 4/252 | 7/506 |
| Esophageal varices hemorrhageGastrointestinal disorders | 0/805 | 4/252 | 4/506 |
| AscitesGastrointestinal disorders | 0/805 | 2/252 | 6/506 |
| Gastrointestinal hemorrhageGastrointestinal disorders | 0/805 | 0/252 | 5/506 |
| AnemiaBlood and lymphatic system disorders | 0/805 | 2/252 | 5/506 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/805 | 1/252 | 5/506 |
| Urinary tract infectionInfections and infestations | 1/805 | 2/252 | 1/506 |
| Event | Eltrombopag: OL Phase | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase |
|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 0/805 | 90/252 | 200/506 |
| NeutropeniaBlood and lymphatic system disorders | 0/805 | 83/252 | 139/506 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/805 | 83/252 | 61/506 |
| PyrexiaGeneral disorders | 0/805 | 60/252 | 141/506 |
| FatigueGeneral disorders | 0/805 | 53/252 | 124/506 |
| HeadacheNervous system disorders | 0/805 | 50/252 | 95/506 |
| Influenza like illnessGeneral disorders | 0/805 | 36/252 | 100/506 |
| Decreased appetiteMetabolism and nutrition disorders | 0/805 | 36/252 | 94/506 |
| NauseaGastrointestinal disorders | 0/805 | 38/252 | 92/506 |
| DiarrheaGastrointestinal disorders | 0/805 | 24/252 | 92/506 |
| Age Continuous(Years) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase | Total |
|---|---|---|---|
| Mean | 52.0 ± 9.15 | 52.4 ± 8.61 | 52.3 ± 8.79 |
| Sex: Female, Male(Participants) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase | Total |
|---|---|---|---|
| Female | 93 | 185 | 278 |
| Male | 160 | 321 | 481 |
| Race/Ethnicity, Customized(participants) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase | Total |
|---|---|---|---|
| African American (A)/African | 4 | 8 | 12 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| White (W) | 188 | 388 | 576 |
| Central/South Asian | 16 | 43 | 59 |
| Japanese/East Asian /South East Asian | 45 | 64 | 109 |
| American Indian or Alaska Native and White | 0 | 1 | 1 |
| African A/African and A Indian/Alaska Native and W | 0 | 1 | 1 |
| Number of participants categorized into the indicated genotype for Hepatitic C Virus (HCV)(participants) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase | Total |
|---|---|---|---|
| Genotype 1 | 160 | 320 | 480 |
| Genotype 2 | 28 | 40 | 68 |
| Genotype 3 | 47 | 113 | 160 |
| Genotype 4 | 17 | 30 | 47 |
| Genotype 5 | 0 | 0 | 0 |
| Genotype 6 | 0 | 1 | 1 |
| Genotype 7 | 0 | 0 | 0 |
| Missing | 1 | 2 | 3 |
| Number of participants categorized into the indicated Child-Pugh (CP) Class(participants) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase | Total |
|---|---|---|---|
| Class A | 242 | 487 | 729 |
| Class B | 11 | 17 | 28 |
| Class C | 0 | 0 | 0 |
| Missing | 0 | 2 | 2 |
| Number of participants with or without previous interferon (IFN) use(participants) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase | Total |
|---|---|---|---|
| Naïve | 182 | 347 | 529 |
| Experienced | 71 | 159 | 230 |
| Number of participants with the indicated FibroTest/Acti Test (FibroSURE) score(participants) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase | Total |
|---|---|---|---|
| Score: F0/F1/F2 | 19 | 46 | 65 |
| Score: F3/F4 | 199 | 405 | 604 |
| Missing | 35 | 55 | 90 |
| Number of participants with normal or elevated Baseline values for Alanine Aminotransferase (ALT)(participants) | Placebo+Antiviral Therapy: DB Phase | Eltrombopag+Antiviral Therapy: DB Phase | Total |
|---|---|---|---|
| Normal | 49 | 113 | 162 |
| Elevated | 204 | 393 | 597 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 227 sites across 23 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2007, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag